Código QR

Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutation

Background: Osimertinib is a standard treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). The EGFR C797S mutation is one of the most common resistant mechanisms to osimertinib. Based on our preclinical data, the safety and efficacy of brigatinib combined with panitumumab was eval...

Descrición completa

Gardado en:
Principais autores: Hiroki Izumi, Tomohiro Sakamoto, Ken Uchibori, Kazumi Nishino, Jun Sakakibara-Konishi, Ryohei Katayama, Shogo Nomura, Shingo Matsumoto, Hibiki Udagawa, Yuji Shibata, Tetsuya Sakai, Kaname Nosaki, Yoshitaka Zenke, Kiyotaka Yoh, Seiji Niho, Koichi Goto
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2026-01-01
Series:Cancer Treatment and Research Communications
Assuntos:
EGFR mutation
Osimertinib
Acquired resistance
C797S
Brigatinib
Panitumumab
Acceso en liña:http://www.sciencedirect.com/science/article/pii/S2468294226000146
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares